Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Entera Bio Ltd.

Report final 6-month results, including bone mineral density data, from the EB613 Phase 2 trial

Delivered after the deadline (47 days after the deadline)

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
11 Mar 2021
Due
30 Jun 2021
Delivered
16 Aug 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“We look forward to reporting the final results, including the 6-month BMD data, from this trial in the second quarter of 2021”

What we found

Evidence strength A What the grades mean

Final 6-month EB613 Phase 2 BMD results were reported on August 16, 2021, after the end of Q2 2021 deadline; an August 2 filing still described the trial as ongoing.

  • A
    Entera Bio Ltd. 6-K filed 2021-08-02 Regulatory filing · published 2 Aug 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results” ✓ confirmed on the page
  • A
    Entera Bio Ltd. 6-K filed 2021-08-16 Regulatory filing · published 16 Aug 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “Final topline results from Entera's Phase 2 clinical trial of EB613, an oral formulation of human parathyroid hormone (1-34)” ✓ confirmed on the page
  • A
    Entera Bio Ltd. 6-K filed 2021-08-16 Regulatory filing · published 16 Aug 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met” ✓ confirmed on the page

Checked 27 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Report
Deliverable
Final 6-month EB613 Phase 2 results including BMD data
In the company’s control
Medium
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Entera Bio Ltd.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-ENTX-025627 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.